Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWVCF3)

Drug Name
Fusidic Acid Drug Info
Synonyms
FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Actinomycosis Approved [2]
Acute gonococcal cervicitis Approved [3]
Acute gonococcal epididymo-orchitis Approved [3]
Anthrax 1B97 Approved [4]
Bacteremia 1A73 Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Bartonellosis Approved [3]
Blepharoconjunctivitis Approved [7]
Boutonneuse fever Approved [3]
Brill-Zinsser disease Approved [3]
Bronchitis CA20 Approved [8]
Brucellosis Approved [3]
Chancroid Approved [3]
Chlamydiaceae infections Approved [9]
Cholangitis Approved [3]
Corneal abrasion NA06.4 Approved [10]
Cutaneous anthrax Approved [3]
Dacryocystitis Approved [11]
Demodex blepharitis 1G07 Approved [3]
Endemic typhus Approved [3]
Epidemic louse-borne typhus Approved [3]
Folliculitis Approved [12]
Gastrointestinal anthrax Approved [3]
Inhalational anthrax Approved [3]
Listeriosis Approved [13]
Lymphogranuloma venereum Approved [3]
Mycoplasma pneumoniae pneumonia Approved [3]
Neonatal sepsis Approved [14]
Ornithosis Approved [3]
Paronychia 1F23.13 Approved [15]
Peritonitis Approved [16]
Pneumococcal infection CA00-CA40 Approved [17]
Pneumonia CA40 Approved [18]
Pseudomonas aeruginosa infectious disease Approved [19]
Q fever Approved [3]
Relapsing fever Approved [3]
Rickettsialpox Approved [3]
Rickettsiosis Approved [3]
Rocky mountain spotted fever Approved [3]
Rosacea ED90.0 Approved [20]
Staphylococcal pneumonia Approved [21]
Staphylococcus aureus infection Approved [22]
Streptococcus infection 1B53 Approved [23]
Syphilis Approved [24]
Trachoma Approved [3]
Tularemia 1B94 Approved [3]
Typhus Approved [3]
Urinary tract infection GC08 Approved [25]
Yaws Approved [3]
MRSA infection 1D01.0Y Phase 3 [26]
Sinusitis CA0A.Z Investigative [27]
Vibrio cholerae infection 1A00 Investigative [3]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
3000226
ChEBI ID
CHEBI:29013
CAS Number
CAS 6990-06-3
TTD Drug ID
DMWVCF3
INTEDE Drug ID
DR0758

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Streptococcus Elongation factor G (Stre-coc fusA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanosine-5'-Diphosphate DM0MUKQ Discovery agent N.A. Investigative [32]
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [35]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [36]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [37]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [39]
Metronidazole DMTIVEN Abscess Approved [40]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [41]
Ethanol DMDRQZU Chronic pain MG30 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [43]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [44]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [45]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [47]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [48]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [49]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [50]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [51]
Propranolol DM79NTF Angina pectoris BA40 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [30]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [53]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [53]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [54]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [30]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [53]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [55]
Gefitinib DM15F0X Colon adenocarcinoma Approved [30]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [56]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B3 (SLCO1B3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [57]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [58]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [59]
Trospium chloride DM32XZT Discovery agent N.A. Approved [60]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [61]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [62]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [63]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [61]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [64]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [66]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [67]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [54]
Repaglinide DM5SXUV Diabetic complication 5A2Y Approved [68]
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [70]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [71]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [71]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [59]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [72]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Streptococcus Elongation factor G (Stre-coc fusA) TT6HP1T EFG_STRZJ Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [28]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [29]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [30]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Gene/Protein Processing [31]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Gene/Protein Processing [31]

References

1 Curcumin/Fusidic Acid Bitherapy Loaded Mixed Micellar Nanogel for Acne Vulgaris Treatment: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2023 Sep 11;24(7):182.
2 [In vitro sensitivity of Actinomyces israelii, Actinobacillus actinomycetem-comitans and Bacteroides melaninogenicus to cephalothin, cephaloridine, gentamicin, fusidic acid and lincomycin]. Int Z Klin Pharmakol Ther Toxikol. 1970 Oct;3(4):318-20.
3 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
4 Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities. Int J Pharm. 2013 Dec 15;458(1):25-30.
5 Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
6 Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
7 Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists. Ophthalmic Physiol Opt. 2006 Jul;26(4):343-61.
8 [Interferon-gamma receptor 1 deficiency in a 19-month-old child: case report and literature review]. Zhonghua Er Ke Za Zhi. 2014 May;52(5):387-91.
9 The in vitro effects of proxymetacaine, fluorescein, and fusidic acid on real-time PCR assays used for the diagnosis of Feline herpesvirus 1 and Chlamydophila felis infections. Vet Ophthalmol. 2011 Sep;14 Suppl 1:5-8.
10 Antibiotic prophylaxis for corneal abrasion. Cochrane Database Syst Rev. 2022 May 27;5(5):CD014617.
11 [Susceptibility of drug-resistant staphylococci isolated from different parts of the ocular anterior segment to common ophthalmic antibiotics]. Zhonghua Yan Ke Za Zhi. 2022 Aug 11;58(8):598-605.
12 Fusidic acid betamethasone lipid cream. Int J Clin Pract. 2016 May;70 Suppl 184:4-13.
13 Antimicrobial Resistance of Listeria monocytogenes from Animal Foods to First- and Second-Line Drugs in the Treatment of Listeriosis from 2008 to 2021: A Systematic Review and Meta-Analysis. Can J Infect Dis Med Microbiol. 2022 Oct 7;2022:1351983.
14 Microbiological Characteristics and Resistance Patterns in a Neonatal Intensive Care Unit: A Retrospective Surveillance Study. Cureus. 2024 Mar 12;16(3):e56027.
15 Extensive pyomyositis secondary to paronychia-related MRSA infection: A case report. Medicine (Baltimore). 2022 Jan 14;101(2):e28431.
16 An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis. J Med Microbiol. 1992 Feb;36(2):71-7.
17 Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist. 1995 Summer;1(2):121-5.
18 Mycoplasma pneumoniae-associated mucositis. BMJ Case Rep. 2021 Apr 15;14(4):e239086.
19 Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon. Pan Afr Med J. 2022 May 18;42:52.
20 Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995 Jan;79(1):42-5.
21 Fusidic acid in other infections. Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S11-5.
22 Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat Antiinfect Drug Discov. 2008 Jan;3(1):10-33.
23 Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35.
24 Balanoposthitis and Penile Edema: Atypical Manifestations of Primary Syphilis. Sex Transm Dis. 2015 Sep;42(9):524-5.
25 Isolation of Staphylococcus aureus Urinary Tract Infections at a Community-Based Healthcare Center in Riyadh. Cureus. 2023 Feb 18;15(2):e35140.
26 Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9.
27 Facial cellulitis associated with Pseudomonas aeruginosa complicating ophthalmic herpes zoster. Dermatol Online J. 2004 Oct 15;10(2):20.
28 The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
29 Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94.
30 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
31 Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chem Res Toxicol. 2016 Oct 17;29(10):1778-1788. doi: 10.1021/acs.chemrestox.6b00262. Epub 2016 Oct 4.
32 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
33 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
34 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
35 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
36 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
37 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
38 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
39 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
40 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
41 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
42 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
43 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
44 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
45 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
46 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
47 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
48 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
49 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
50 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
51 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
52 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
53 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
54 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
55 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
56 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
57 Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
58 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
59 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
60 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
61 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
62 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
63 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
64 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
65 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
66 Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
67 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
68 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
69 SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
70 SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
71 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
72 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.